Federated Hermes Inc. Has $337,000 Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Federated Hermes Inc. cut its position in Royalty Pharma plc (NASDAQ:RPRX) by 40.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,000 shares of the biopharmaceutical company’s stock after selling 8,000 shares during the quarter. Federated Hermes Inc.’s holdings in Royalty Pharma were worth $337,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in RPRX. Allworth Financial LP grew its position in shares of Royalty Pharma by 89.8% in the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 451 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Royalty Pharma by 112.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 531 shares during the period. Rakuten Securities Inc. acquired a new position in Royalty Pharma during the fourth quarter worth approximately $110,000. PNC Financial Services Group Inc. raised its stake in Royalty Pharma by 10.8% in the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 536 shares during the period. Finally, Park Place Capital Corp lifted its position in shares of Royalty Pharma by 52.2% in the fourth quarter. Park Place Capital Corp now owns 5,656 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 1,939 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX opened at $28.41 on Friday. Royalty Pharma plc has a 12-month low of $25.92 and a 12-month high of $35.70. The company’s 50 day moving average price is $29.36 and its two-hundred day moving average price is $28.58. The firm has a market cap of $16.97 billion, a PE ratio of 15.03 and a beta of 0.47. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a return on equity of 26.93% and a net margin of 48.22%. The business had revenue of $736.00 million for the quarter, compared to the consensus estimate of $702.90 million. Equities research analysts predict that Royalty Pharma plc will post 3.95 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.96%. The ex-dividend date is Thursday, May 16th. Royalty Pharma’s payout ratio is currently 44.44%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. decreased their target price on Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating on the stock in a report on Tuesday, February 20th. StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, April 11th. Bank of America cut their target price on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, April 12th. Finally, The Goldman Sachs Group decreased their target price on Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 20th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $46.75.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.